Logo image of CRBU

CARIBOU BIOSCIENCES INC (CRBU) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:CRBU - US1420381089 - Common Stock

1.71 USD
-0.08 (-4.47%)
Last: 12/15/2025, 6:59:15 PM
1.74 USD
+0.03 (+1.75%)
After Hours: 12/15/2025, 6:59:15 PM
Fundamental Rating

3

CRBU gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 529 industry peers in the Biotechnology industry. CRBU scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, CRBU is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

CRBU had negative earnings in the past year.
In the past year CRBU has reported a negative cash flow from operations.
In the past 5 years CRBU always reported negative net income.
CRBU had a negative operating cash flow in each of the past 5 years.
CRBU Yearly Net Income VS EBIT VS OCF VS FCFCRBU Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

CRBU has a Return On Assets of -80.58%. This is in the lower half of the industry: CRBU underperforms 68.81% of its industry peers.
CRBU's Return On Equity of -110.77% is in line compared to the rest of the industry. CRBU outperforms 43.10% of its industry peers.
Industry RankSector Rank
ROA -80.58%
ROE -110.77%
ROIC N/A
ROA(3y)-32.6%
ROA(5y)-41.65%
ROE(3y)-39.9%
ROE(5y)-65.73%
ROIC(3y)N/A
ROIC(5y)N/A
CRBU Yearly ROA, ROE, ROICCRBU Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CRBU so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CRBU Yearly Profit, Operating, Gross MarginsCRBU Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K

More info and screens

6

2. Health

2.1 Basic Checks

CRBU does not have a ROIC to compare to the WACC, probably because it is not profitable.
CRBU has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, CRBU has more shares outstanding
CRBU has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CRBU Yearly Shares OutstandingCRBU Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
CRBU Yearly Total Debt VS Total AssetsCRBU Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

Based on the Altman-Z score of -3.85, we must say that CRBU is in the distress zone and has some risk of bankruptcy.
CRBU has a Altman-Z score of -3.85. This is comparable to the rest of the industry: CRBU outperforms 41.02% of its industry peers.
CRBU has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.85
ROIC/WACCN/A
WACC8.83%
CRBU Yearly LT Debt VS Equity VS FCFCRBU Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

CRBU has a Current Ratio of 5.54. This indicates that CRBU is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of CRBU (5.54) is comparable to the rest of the industry.
CRBU has a Quick Ratio of 5.54. This indicates that CRBU is financially healthy and has no problem in meeting its short term obligations.
CRBU's Quick ratio of 5.54 is in line compared to the rest of the industry. CRBU outperforms 59.74% of its industry peers.
Industry RankSector Rank
Current Ratio 5.54
Quick Ratio 5.54
CRBU Yearly Current Assets VS Current LiabilitesCRBU Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

5

3. Growth

3.1 Past

CRBU shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -3.03%.
CRBU shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -19.00%.
The Revenue has been growing by 11.54% on average over the past years. This is quite good.
EPS 1Y (TTM)-3.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.05%
Revenue 1Y (TTM)-19%
Revenue growth 3Y1.35%
Revenue growth 5Y11.54%
Sales Q2Q%8.6%

3.2 Future

The Earnings Per Share is expected to grow by 8.70% on average over the next years. This is quite good.
Based on estimates for the next years, CRBU will show a very strong growth in Revenue. The Revenue will grow by 61.30% on average per year.
EPS Next Y-1.59%
EPS Next 2Y5.39%
EPS Next 3Y3.41%
EPS Next 5Y8.7%
Revenue Next Year-5.9%
Revenue Next 2Y-0.62%
Revenue Next 3Y5%
Revenue Next 5Y61.3%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CRBU Yearly Revenue VS EstimatesCRBU Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B 4B 5B
CRBU Yearly EPS VS EstimatesCRBU Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -0.5 -1 -1.5 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CRBU. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CRBU. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CRBU Price Earnings VS Forward Price EarningsCRBU Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRBU Per share dataCRBU EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y5.39%
EPS Next 3Y3.41%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CRBU!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

CARIBOU BIOSCIENCES INC

NASDAQ:CRBU (12/15/2025, 6:59:15 PM)

After market: 1.74 +0.03 (+1.75%)

1.71

-0.08 (-4.47%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2025-11-12/amc
Earnings (Next)03-02 2026-03-02/amc
Inst Owners38.24%
Inst Owner Change-9.73%
Ins Owners4.32%
Ins Owner Change0%
Market Cap159.83M
Revenue(TTM)9.29M
Net Income(TTM)-157.13M
Analysts85.71
Price Target11.35 (563.74%)
Short Float %6.73%
Short Ratio2.08
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-13.34%
Min EPS beat(2)-45.06%
Max EPS beat(2)18.38%
EPS beat(4)3
Avg EPS beat(4)-3.23%
Min EPS beat(4)-45.06%
Max EPS beat(4)18.38%
EPS beat(8)5
Avg EPS beat(8)-0.45%
EPS beat(12)9
Avg EPS beat(12)7.25%
EPS beat(16)12
Avg EPS beat(16)6.44%
Revenue beat(2)1
Avg Revenue beat(2)-8.7%
Min Revenue beat(2)-23.49%
Max Revenue beat(2)6.09%
Revenue beat(4)2
Avg Revenue beat(4)2.78%
Min Revenue beat(4)-23.49%
Max Revenue beat(4)31.82%
Revenue beat(8)3
Avg Revenue beat(8)-6.92%
Revenue beat(12)7
Avg Revenue beat(12)52.34%
Revenue beat(16)8
Avg Revenue beat(16)37.54%
PT rev (1m)25.61%
PT rev (3m)25.61%
EPS NQ rev (1m)6.15%
EPS NQ rev (3m)5.82%
EPS NY rev (1m)3.43%
EPS NY rev (3m)-1.13%
Revenue NQ rev (1m)-19.81%
Revenue NQ rev (3m)-22.77%
Revenue NY rev (1m)-8.81%
Revenue NY rev (3m)-9.77%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 17.2
P/FCF N/A
P/OCF N/A
P/B 1.13
P/tB 1.13
EV/EBITDA N/A
EPS(TTM)-1.7
EYN/A
EPS(NY)-1.47
Fwd EYN/A
FCF(TTM)-1.37
FCFYN/A
OCF(TTM)-1.34
OCFYN/A
SpS0.1
BVpS1.52
TBVpS1.52
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -80.58%
ROE -110.77%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-32.6%
ROA(5y)-41.65%
ROE(3y)-39.9%
ROE(5y)-65.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 50.47%
Cap/Sales 22.52%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.54
Quick Ratio 5.54
Altman-Z -3.85
F-Score3
WACC8.83%
ROIC/WACCN/A
Cap/Depr(3y)283.95%
Cap/Depr(5y)220.75%
Cap/Sales(3y)43.03%
Cap/Sales(5y)30.75%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-3.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.05%
EPS Next Y-1.59%
EPS Next 2Y5.39%
EPS Next 3Y3.41%
EPS Next 5Y8.7%
Revenue 1Y (TTM)-19%
Revenue growth 3Y1.35%
Revenue growth 5Y11.54%
Sales Q2Q%8.6%
Revenue Next Year-5.9%
Revenue Next 2Y-0.62%
Revenue Next 3Y5%
Revenue Next 5Y61.3%
EBIT growth 1Y11.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year15.24%
EBIT Next 3Y2.42%
EBIT Next 5YN/A
FCF growth 1Y-18.21%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-29.58%
OCF growth 3YN/A
OCF growth 5YN/A

CARIBOU BIOSCIENCES INC / CRBU FAQ

Can you provide the ChartMill fundamental rating for CARIBOU BIOSCIENCES INC?

ChartMill assigns a fundamental rating of 3 / 10 to CRBU.


Can you provide the valuation status for CARIBOU BIOSCIENCES INC?

ChartMill assigns a valuation rating of 0 / 10 to CARIBOU BIOSCIENCES INC (CRBU). This can be considered as Overvalued.


Can you provide the profitability details for CARIBOU BIOSCIENCES INC?

CARIBOU BIOSCIENCES INC (CRBU) has a profitability rating of 0 / 10.


Can you provide the financial health for CRBU stock?

The financial health rating of CARIBOU BIOSCIENCES INC (CRBU) is 6 / 10.


Can you provide the expected EPS growth for CRBU stock?

The Earnings per Share (EPS) of CARIBOU BIOSCIENCES INC (CRBU) is expected to decline by -1.59% in the next year.